These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33424349)

  • 1. Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
    Aboul-Soud MAM; Alzahrani AJ; Mahmoud A
    Saudi J Biol Sci; 2021 Jan; 28(1):628-634. PubMed ID: 33424349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schisandra chinensis regulates drug metabolizing enzymes and drug transporters via activation of Nrf2-mediated signaling pathway.
    He JL; Zhou ZW; Yin JJ; He CQ; Zhou SF; Yu Y
    Drug Des Devel Ther; 2015; 9():127-46. PubMed ID: 25552902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.
    Reimer T; Kempert S; Gerber B; Thiesen HJ; Hartmann S; Koczan D
    BMC Cancer; 2016 May; 16():337. PubMed ID: 27234217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
    Ozawa S
    Rinsho Byori; 2003 Feb; 51(2):168-73. PubMed ID: 12690635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.
    Yiannakopoulou ECh
    Pharmacogenomics J; 2013 Apr; 13(2):105-9. PubMed ID: 23044602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
    Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
    Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
    Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
    Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance.
    Swart M; Dandara C
    Front Genet; 2014; 5():167. PubMed ID: 24926315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of phase I, II and III drug metabolism/transport by xenobiotics.
    Xu C; Li CY; Kong AN
    Arch Pharm Res; 2005 Mar; 28(3):249-68. PubMed ID: 15832810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
    Sim SC; Kacevska M; Ingelman-Sundberg M
    Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine.
    Couto N; Al-Majdoub ZM; Gibson S; Davies PJ; Achour B; Harwood MD; Carlson G; Barber J; Rostami-Hodjegan A; Warhurst G
    Drug Metab Dispos; 2020 Apr; 48(4):245-254. PubMed ID: 31959703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
    Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine.
    Ahmed S; Zhou Z; Zhou J; Chen SQ
    Genomics Proteomics Bioinformatics; 2016 Oct; 14(5):298-313. PubMed ID: 27729266
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Zhang L; Sarangi V; Ho MF; Moon I; Kalari KR; Wang L; Weinshilboum RM
    Drug Metab Dispos; 2021 May; 49(5):395-404. PubMed ID: 33658230
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
    Arrigoni E; Del Re M; Fidilio L; Fogli S; Danesi R; Di Paolo A
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.